← DocMath

Hepatology medical calculators

All 120 Hepatology medical calculators on DocMath, A–Z. All specialties

50-50 criteria (post-hepatectomy, day 5)Early predictor of death after hepatectomy: prothrombin time <50% and bilirubin >50 µmol/L on postoperative day 5.
AARC-ACLF score (APASL)Grades severity of APASL-defined acute-on-chronic liver failure and predicts 28-day mortality.
ABIC scoreAge-Bilirubin-INR-Creatinine prognostic score in alcohol-associated hepatitis.
Acetaminophen treatment nomogram (US/Canada)Checks a serum acetaminophen level drawn 4–24 h after a single acute ingestion against the 150 treatment line used in Canada and the US.
ACLF diagnosis & grade (2026 global consensus)Applies the 2026 AASLD/EASL/APASL/ALEH/SOLDA harmonised definition: diagnoses acute-on-chronic liver failure, its type (A/B) and grade (1–3).
Agile 3+ (advanced fibrosis, FibroScan-based)Probability of advanced fibrosis (F≥3) in MASLD from liver stiffness, AST/ALT ratio, platelets, diabetes, sex and age.
Agile 4 (cirrhosis, FibroScan-based)Probability of cirrhosis (F4) in MASLD from liver stiffness, AST/ALT ratio, platelets, diabetes and sex.
AKI and HRS-AKI in cirrhosis (ICA-ADQI 2024)Stages AKI in cirrhosis by creatinine and urine output, applies the 2024 ICA-ADQI HRS-AKI criteria, and grades the response to vasoconstrictor treatment.
ALBI grade (albumin-bilirubin)Objective liver-function grade, used especially in hepatocellular carcinoma; separates Child-Pugh A into prognostic groups.
Albumin replacement for large-volume paracentesisAlbumin dose to prevent post-paracentesis circulatory dysfunction after large-volume paracentesis in cirrhosis.
ALFSG prognostic model (21-day transplant-free survival in ALF)Predicts 21-day transplant-free survival in acute liver failure from admission data (US Acute Liver Failure Study Group, Koch 2016).
ALP:bilirubin and AST:ALT ratios (Wilson disease in acute liver failure)Rapid screen for Wilson disease as the cause of acute liver failure: ALP:total bilirubin <4 and AST:ALT >2.2.
aMAP score (HCC risk in chronic hepatitis)5-year hepatocellular carcinoma risk in adults with chronic hepatitis (HBV, HCV, non-viral) from age, sex, albumin–bilirubin and platelets.
Amsterdam-Oxford model (PSC)Transplant-free survival (free of liver transplant or PSC-related death) in primary sclerosing cholangitis, from values at diagnosis or updated during follow-up.
Animal Naming Test (S-ANT1) for covert hepatic encephalopathyBedside screen for minimal / grade 1 (covert) hepatic encephalopathy: animals named in 1 minute, adjusted for age and education.
APRI (AST-to-Platelet Ratio Index)Non-invasive fibrosis/cirrhosis estimate, validated in hepatitis C.
ART score (retreatment with TACE)Assessment for Retreatment with TACE: identifies patients with poor prognosis before a second TACE session, from changes after the first session.
Ascites grade and refractory ascites (ICA, EASL, AASLD)Grades ascites in cirrhosis (ICA grades 1–3) and applies the criteria for diuretic-resistant, diuretic-intractable and recurrent ascites.
Ascitic neutrophil count and SBP diagnosis (with RBC correction)Corrects the ascitic PMN count for blood, classifies SBP, culture-negative neutrocytic ascites and bacterascites, and gives the albumin regimen for SBP.
Autoimmune hepatitis — simplified criteria (IAIHG 2008)Simplified diagnostic score for autoimmune hepatitis.
BAR score (balance of risk, liver transplantation)Balance of donor and recipient risk for 3-month patient survival after deceased-donor (brain-death), whole-graft liver transplantation; above 18 marks poor donor–recipient matches.
BARD score (MASLD fibrosis)Simple rule-out score for advanced fibrosis in fatty liver disease.
Baveno VIII criteria (cACLD, CSPH, screening endoscopy)Applies the Baveno VIII consensus (2026) to liver stiffness (transient elastography), platelets and optional spleen stiffness: cACLD likelihood, clinically significant portal hypertension, and need for variceal screening.
BCLC staging and treatment strategy (2026 update)Barcelona Clinic Liver Cancer stage (0, A, B, C, D) for hepatocellular carcinoma, with the first-line treatment option and expected median survival from the BCLC flowchart.
BCS-TIPS prognostic indexPredicts death or transplant within 1 year after TIPS for Budd-Chiari syndrome.
Child-Pugh scoreSeverity of cirrhosis.
Chronic hepatitis B: treatment eligibility (CASL/AMMI 2025 vs AASLD-IDSA 2025)Applies the 2025 Canadian (CASL/AMMI) and US (AASLD-IDSA) treatment criteria to an HBsAg-positive adult and shows where they differ.
Cirrhotic cardiomyopathy — CCM Consortium criteria (2019/2020)Echocardiographic diagnosis of cirrhotic cardiomyopathy (systolic or advanced diastolic dysfunction) in cirrhosis without other heart disease.
Clichy criteria (acute liver failure)French criteria for emergency liver transplantation in fulminant / subfulminant hepatitis: encephalopathy plus factor V below an age-specific threshold.
CLIF-C ACLF score & EASL-CLIF (2013) ACLF gradeGrades acute-on-chronic liver failure by the original EASL-CLIF (2013) criteria and estimates prognosis in patients with cirrhosis and acute decompensation.
CLIF-C AD score (acute decompensation without ACLF)Prognosis in hospitalized patients with cirrhosis and acute decompensation who do not have ACLF.
CLIP score (Cancer of the Liver Italian Program)Prognostic score for hepatocellular carcinoma combining Child-Pugh stage, tumor morphology, AFP and portal vein thrombosis (0–6).
CU-HCC score (chronic hepatitis B)HCC risk in adults with chronic hepatitis B from age, albumin, bilirubin, HBV DNA and clinical cirrhosis (Chinese University of Hong Kong).
D-MELD (donor age × recipient MELD)Donor–recipient matching statistic for deceased-donor liver transplantation: the product of donor age and the recipient’s laboratory MELD.
DILI severity (DILIN) with Hy's law and nRGrades drug-induced liver injury severity (DILIN 1–5) and checks Hy's law and the new R ratio (nR).
Donor Risk Index (DRI, liver graft failure)Relative risk of liver graft failure from deceased-donor and transplant characteristics (US SRTR data 1998–2002).
Early allograft dysfunction (Olthoff criteria)Binary definition of early allograft dysfunction after deceased-donor liver transplant, from bilirubin and INR on day 7 and peak aminotransferases in week 1.
Enhanced Liver Fibrosis (ELF) scoreInterprets the ELF score (or calculates it from hyaluronic acid, PIIINP and TIMP-1) against the CASL 2026, NICE NG49 and FDA-labelled thresholds.
Eurotransplant Donor Risk Index (ET-DRI)Deceased-donor liver graft quality, Eurotransplant-specific (reference only in Canada): the Feng DRI without race and height, plus cold ischemia, latest donor GGT and rescue allocation.
FAST score (FibroScan-AST)Probability of at-risk MASH (steatohepatitis with NAFLD activity score ≥4 and fibrosis stage ≥F2) from FibroScan liver stiffness, CAP and AST.
Fatty Liver Index (FLI)Probability-based index (0–100) of hepatic steatosis from BMI, waist circumference, triglycerides and GGT.
FIB-4 indexNon-invasive estimate of advanced liver fibrosis.
Forns index (fibrosis in chronic hepatitis C)Identifies patients with chronic hepatitis C without significant fibrosis (Scheuer F2–F4) from age, GGT, cholesterol and platelet count.
Freiburg index of post-TIPS survival (FIPS)Survival after elective TIPS for refractory ascites or secondary prophylaxis of variceal bleeding; identifies high-risk candidates (FIPS ≥0.92).
French AFP model (HCC transplant selection)Risk of HCC recurrence after liver transplantation from tumor size, nodule number and AFP; ≤2 points = low risk (adopted for listing in France).
GAG-HCC score (chronic hepatitis B)5- and 10-year HCC risk in chronic hepatitis B from gender, age, HBV DNA, core promoter mutations and cirrhosis (Hong Kong).
GALAD score (HCC detection: gender, age, AFP-L3, AFP, DCP)Probability that a patient with chronic liver disease has hepatocellular carcinoma, from sex, age and three serum biomarkers (AFP, AFP-L3%, DCP/PIVKA-II).
Glasgow Alcoholic Hepatitis ScorePrognosis in alcohol-associated hepatitis.
GLOBE score (PBC on ursodeoxycholic acid)Transplant-free survival in primary biliary cholangitis after 1 year of ursodeoxycholic acid (UDCA), with the response threshold against a matched general population.
HAP score (TACE prognosis)Survival after transarterial (chemo)embolisation for hepatocellular carcinoma, from albumin, bilirubin, AFP and tumor size, assessed before the first TACE.
HBV reactivation risk with immunosuppression (AGA 2025)Risk category of hepatitis B reactivation by HBV serology and drug class, with the AGA 2025 prophylaxis or monitoring recommendation.
HCV simplified treatment eligibility (AASLD-IDSA)Checks eligibility for the AASLD-IDSA simplified hepatitis C treatment pathway for treatment-naive adults, with or without compensated cirrhosis.
Hepamet Fibrosis Score (HFS)Probability of advanced fibrosis (F3–F4) in MASLD/NAFLD from routine variables, including HOMA-IR or diabetes.
Hepatic Steatosis Index (HSI)Simple steatosis screening index from the ALT/AST ratio, BMI, sex and diabetes.
Hepatic venous pressure gradient (HVPG) interpretationCalculates HVPG (wedged minus free hepatic venous pressure) and interprets it by the Baveno VII and VIII consensus for the clinical setting.
Hepatitis B serology interpretation (triple panel)Interprets HBsAg, total anti-HBc, IgM anti-HBc and anti-HBs results using the CDC interpretation table.
Hepatopulmonary syndrome — diagnosis and severity (ERS / ILTS 2016)Diagnosis of HPS (liver disease or portal hypertension, intrapulmonary vascular dilatation, raised A–a gradient) and ERS severity grade by PaO₂.
Intrahepatic cholestasis of pregnancy — bile acid bands (SOGC 2024)Diagnosis and birth-timing bands for intrahepatic cholestasis of pregnancy from the peak non-fasting total bile acid level.
King's College Criteria (acute liver failure)Identifies acute liver failure patients who should be referred for transplantation.
King's Score (fibrosis in chronic hepatitis C)Non-invasive prediction of cirrhosis and significant fibrosis in chronic hepatitis C.
Leipzig score (Wilson's disease diagnosis)Diagnostic scoring system for Wilson's disease. Not on MDCalc; added for this site's focus.
Lille + MELD combined model (alcohol-associated hepatitis)2- and 6-month mortality in severe alcohol-associated hepatitis treated with corticosteroids, combining the day-7 Lille score and baseline MELD.
Lille modelResponse to corticosteroids at day 7 in severe alcohol-associated hepatitis.
Liver Frailty Index (LFI)Performance-based frailty in cirrhosis (grip, chair stands, balance) with AASLD 2021 robust/pre-frail/frail cut-offs.
Liver stiffness (FibroScan) interpretation by etiologyInterprets a vibration-controlled transient elastography (FibroScan) liver stiffness value with Baveno VIII and the etiology-specific thresholds of CASL 2026, EASL 2021 and AASLD 2025.
LSM-HCC score (chronic hepatitis B)5-year HCC risk in chronic hepatitis B, replacing clinical cirrhosis in CU-HCC with transient elastography liver stiffness.
Maddrey's Discriminant FunctionSeverity of alcohol-associated hepatitis; steroid eligibility.
MEAF score (Model for Early Allograft Function)Continuous 0–10 grading of early graft function after liver transplant from peak ALT and INR over days 1–3 and day-3 bilirubin.
MEFIB index (MRE + FIB-4)Rules in or out significant fibrosis (stage ≥2) in MASLD by combining MR elastography with FIB-4.
MELD (original, pre-2016)3-month mortality in chronic liver disease; former UNOS allocation score.
MELD 3.0Updated MELD adding sex and albumin; current US allocation score (age ≥12).
MELD-based 6-week mortality after acute variceal bleeding6-week mortality in cirrhosis with acute esophageal variceal bleeding, from MELD at admission (Reverter 2014).
MELD-lactate (inpatient mortality)Inpatient mortality in hospitalized chronic liver disease from admission MELD and lactate (Sarmast 2020).
MELD-Na (OPTN 2016)MELD with sodium; US liver transplant allocation score 2016–2023.
MELD-Plus (90-day mortality after a cirrhosis admission)Risk of death within 90 days of discharge after a cirrhosis-related admission (Kartoun 2017).
MELD-Sarcopenia and CT sarcopenia (L3 skeletal muscle index)Calculates the L3 skeletal muscle index from CT, classifies sarcopenia in cirrhosis and adds it to MELD (MELD-Sarcopenia) for mortality prediction.
MELD-XI (MELD excluding INR)MELD-scale prognostic score without INR, for cirrhosis when INR is raised by oral anticoagulation.
Milan criteria (HCC transplant eligibility)Liver transplant eligibility for hepatocellular carcinoma.
Modified PAGE-B (mPAGE-B) score5-year hepatocellular carcinoma risk in Asian adults with chronic hepatitis B starting entecavir or tenofovir.
NACSELD-ACLF (extrahepatic organ failures)Bedside North American definition of ACLF (two or more extrahepatic organ failures) in hospitalized patients with cirrhosis, with 30-day survival by number of failures.
NAFLD (MASLD) Fibrosis ScoreAdvanced fibrosis in fatty liver disease.
NAFLD liver fat score and liver fat equation (Kotronen)Predicts increased liver fat (≥5.56% on proton MR spectroscopy) from metabolic syndrome, type 2 diabetes, fasting insulin, AST and the AST/ALT ratio, and estimates liver fat percentage.
New Wilson Index (revised King's score for Wilson disease)Predicts death without liver transplantation in Wilson disease presenting with liver failure (score ≥11).
NIAAA criteria for alcohol-associated hepatitisClassifies a suspected alcohol-associated hepatitis as definite, probable or possible (NIAAA Alcoholic Hepatitis Consortia 2016).
Non-Ceruloplasmin Bound Copper (NCC)Wilson's disease treatment monitoring.
Okuda staging (hepatocellular carcinoma)Three-stage prognostic staging of HCC from tumor size relative to the liver, ascites, albumin and bilirubin.
PAGE-B (HCC risk in chronic hepatitis B)Five-year hepatocellular carcinoma risk in adults with chronic hepatitis B on entecavir or tenofovir.
Paris criteria (PBC with features of AIH)Defines primary biliary cholangitis with features of autoimmune hepatitis (PBC–AIH overlap/variant).
Portopulmonary hypertension — hemodynamic criteria and transplant riskRight-heart-catheter diagnosis of portopulmonary hypertension (2022 ESC/ERS and ILTS 2016 definitions) and ILTS mPAP thresholds for liver transplantation.
Post-hepatectomy liver failure — ISGLS definition and gradeISGLS 2011 definition of post-hepatectomy liver failure (INR and bilirubin on or after day 5) and grade A/B/C by clinical management.
R factor (drug-induced liver injury pattern)Classifies liver injury as hepatocellular, mixed or cholestatic.
REACH-B score (HCC risk in chronic hepatitis B without cirrhosis)3-, 5- and 10-year hepatocellular carcinoma risk in adults with chronic hepatitis B without cirrhosis (derived in a Taiwanese community cohort aged 30–65).
RECAM (revised electronic causality assessment, DILI)Causality of drug-induced liver injury for one suspected drug (single-agent, non-herbal cases), in five domains with the original diagnostic cut-offs.
RETREAT score (HCC recurrence after liver transplant)Risk of HCC recurrence after liver transplant for HCC within Milan criteria on imaging, from AFP at transplant and explant pathology; with the authors’ surveillance schedule.
Revised Mayo risk score (PSC)Prognostic risk score in primary sclerosing cholangitis from age, bilirubin, albumin, AST and variceal bleeding (no biopsy needed).
Revised original IAIHG score (autoimmune hepatitis, 1999)Comprehensive diagnostic score for autoimmune hepatitis, before treatment or after the response to treatment is known.
Rotterdam Budd-Chiari scorePrognostic class (and 5-year survival) in Budd-Chiari syndrome at diagnosis.
Royal Free Hospital-Nutritional Prioritizing Tool (RFH-NPT)Screens patients with cirrhosis for malnutrition risk (low, moderate, high) in under 3 minutes, with or without fluid overload.
RUCAM (updated 2016) — DILI causalityAssesses the likelihood that a drug or herb caused liver injury. Score each suspect product separately.
Runyon criteria (secondary bacterial peritonitis)Ascitic-fluid criteria suggesting secondary (gut-perforation) peritonitis rather than SBP in neutrocytic ascites.
SAFE score (Steatosis-Associated Fibrosis Estimator)Identifies low-risk MASLD in primary care: estimates significant fibrosis (≥F2) from age, BMI, diabetes, AST, ALT, globulin and platelets.
SALT score (sustained alcohol use after early liver transplant)Identifies candidates for early liver transplant for severe alcohol-associated hepatitis at low risk of sustained alcohol use afterwards.
SBP antibiotic prophylaxis criteria (Fernández criteria)Checks whether a patient with cirrhosis and ascites meets the criteria for primary prophylaxis of spontaneous bacterial peritonitis, or needs secondary or GI-bleeding prophylaxis.
Serum-Ascites Albumin Gradient (SAAG)Distinguishes portal-hypertensive from other ascites.
Six-and-twelve score (TACE candidates)Survival stratification for recommended TACE candidates (unresectable HCC, Child-Pugh A5–B7, performance status 0) from tumor burden alone.
SOFT and P-SOFT scores (3-month survival after liver transplant)Predicts 3-month recipient mortality after deceased-donor liver transplantation: P-SOFT from recipient factors before allocation, SOFT once donor and logistics factors are known.
SOS/VOD after HSCT — EBMT 2023 adult diagnosis and severityDiagnoses sinusoidal obstruction syndrome/veno-occlusive disease (probable, clinical, proven) and grades its severity in adults after hematopoietic stem cell transplant.
Standardised future liver remnant (sFLR, Vauthey)Standardised total liver volume from body surface area and the future liver remnant as a percentage of it, before major hepatectomy.
Steatotic liver disease classification (MASLD / MetALD / ALD)Applies the 2023 multisociety nomenclature: classifies adult steatotic liver disease as MASLD, MetALD, ALD, combination or other specific etiology, or cryptogenic, from cardiometabolic criteria and weekly alcohol intake.
Swansea criteria (acute fatty liver of pregnancy)Diagnosis of acute fatty liver of pregnancy: ≥6 of 14 features in the absence of another explanation.
Toronto HCC Risk Index (THRI)10-year risk of hepatocellular carcinoma in adults with cirrhosis of any cause, from age, sex, etiology and platelets (Toronto derivation, Rotterdam validation).
UCSF criteria (HCC transplant eligibility)Expanded tumor-size criteria for liver transplantation in hepatocellular carcinoma (beyond Milan).
UDCA response criteria in PBC (Paris I/II, Toronto, Barcelona, POISE)Classifies biochemical response to ursodeoxycholic acid by five published definitions, each applied as in its original paper.
UK DCD Risk Score (DCD liver transplant futility)Donor–recipient risk score for graft loss after donation-after-circulatory-death (DCD) liver transplantation, identifying futile combinations.
UK-PBC risk score (5-, 10-, 15-year)Absolute risk of end-stage liver disease (liver transplant, liver-related death or bilirubin ≥100 µmol/L) within 5, 10 and 15 years in PBC treated with UDCA for 12 months.
UKELD (United Kingdom End-Stage Liver Disease score)UK end-stage liver disease score from INR, creatinine, bilirubin and sodium (Barber 2011), used for elective liver transplant listing in the UK.
Up-to-seven criteria (HCC transplant, Metroticket 1)Liver-transplant selection beyond Milan: the number of tumors plus the size of the largest tumor (cm) must not exceed 7.
VOCAL-Penn score (post-operative mortality in cirrhosis)Predicted 30-, 90- and 180-day post-operative mortality in adults with cirrhosis from age, ASA class, surgery category, emergency indication, NAFLD, obesity, albumin, platelets and bilirubin.
West Haven criteria (hepatic encephalopathy grade)Grades overt hepatic encephalopathy. Descriptive — implement as a selector with the grade definitions.
Yerdel grade of portal vein thrombosisGrades the extent of portal vein thrombosis in liver transplant candidates.